<DOC>
	<DOCNO>NCT00002116</DOCNO>
	<brief_summary>To evaluate safety tolerance topical cidofovir ( HPMPC ) therapy refractory mucocutaneous herpes simplex virus disease AIDS patient . To determine whether topical HPMPC therapy induce re-epithelialization heal refractory mucocutaneous herpes simplex virus disease AIDS patient . To evaluate virologic effect topical HPMPC therapy herpes simplex virus shed refractory lesion .</brief_summary>
	<brief_title>A Phase I/II Study Safety Efficacy Topical 1- ( S ) - ( 3-Hydroxy-2-Phosphonylmethoxypropyl ) Cytosine Dihydrate ( Cidofovir ; HPMPC ) Treatment Refractory Mucocutaneous Herpes Simplex Disease Patients With AIDS</brief_title>
	<detailed_description>Patients randomize receive topical therapy placebo ( vehicle alone ) HPMPC either 0.3 1.0 percent daily 5 day . Patients assess day 15 ; significant toxicity eligible receive open-label topical HPMPC 6 month .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Cidofovir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral therapy AZT , ddI , ddC , d4T . Oral trimethoprim/sulfamethoxazole . Dapsone . Atovaquone . Fluconazole . Rifabutin . Clarithromycin . Patients must : HIV seropositivity . Mucocutaneous herpes simplex virus ( HSV ) infection confirm previous viral culture persist without improvement despite least 10 day acyclovir minimum dose 1 g/day ( oral ) 15 mg/kg/day ( intravenous ) . Measurable lesion . Consent parent guardian le 18 year age . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active medical problem sufficient hinder study compliance assessment treatment effect . Concurrent Medication : Excluded : Acyclovir . Immunomodulators ( corticosteroid interferon ) . Lymphocyte replacement therapy . Biologic response modifier . Ganciclovir . Foscarnet . Vidarabine . Topical trifluridine . Other investigational drug ( except d4T ) . Amphotericin . Intravenous therapy PCP . Chemotherapeutic agent . Prior Medication : Excluded within 14 day prior study entry : Immunomodulators ( corticosteroid interferon ) . Lymphocyte replacement therapy . Biologic response modifier . Ganciclovir . Foscarnet . Vidarabine . Topical trifluridine . Other investigational drug potential antiHSV activity . Amphotericin . Intravenous therapy PCP . Excluded within 4 week prior study entry : Chemotherapeutic agent . Required : At least 10 day prior acyclovir minimum dose 1 g/day ( oral ) 15 mg/kg/day ( intravenous ) . Substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1995</verification_date>
	<keyword>Herpes Simplex</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>cidofovir</keyword>
</DOC>